Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals, has announced a significant supply and transfer agreement with Organon China, a US-based healthcare firm specializing in women’s health. The agreement grants Organon exclusive commercialization rights for Bao Pharma’s SJ02 in mainland China.
SJ02, developed by Centergene, is a cutting-edge long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP). It is designed for controlled ovarian stimulation (COS) in conjunction with a gonadotropin-releasing hormone (GnRH) antagonist, aiming to facilitate the development of multiple follicles in women undergoing assisted reproductive technology (ART) treatments. SJ02 is poised to potentially become the first long-acting FSH available in China and is currently under review by China’s regulatory authorities.
As per the terms of the agreement, BaoPharma and Centergene are set to receive an upfront payment of USD 12 million, with additional payments tied to development and commercial milestones. – Flcube.com
